Harrow Health, Inc. (NASDAQ:HROW) Major Shareholder Opaleye Management Inc. Acquires 50,000 Shares of Stock

Harrow Health, Inc. (NASDAQ:HROW) major shareholder Opaleye Management Inc. acquired 50,000 shares of the stock in a transaction dated Thursday, March 28th. The stock was acquired at an average cost of $12.82 per share, for a total transaction of $641,000.00. Following the purchase, the insider now directly owns 3,745,600 shares in the company, valued at $48,018,592. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

• On Wednesday, March 20th, Opaleye Management Inc. acquired 50,600 shares of Harrow Health stock. The stock was acquired at an average cost of $9.65 per share, for a total transaction of $488,290.00.

Harrow Health Stock Up 3.9 %

NASDAQ HROW opened at $13.23 on Friday. The company has a 50 day moving average price of $10.73 and a two-hundred day moving average price of $11.60. The company has a current ratio of 2.83, a quick ratio of 2.61 and a debt-to-equity ratio of 2.60. Harrow Health, Inc. has a 12-month low of $7.60 and a 12-month high of $28.25.

Hedge Funds Weigh In On Harrow Health

Several large investors have recently bought and sold shares of HROW. Marshall Wace LLP grew its holdings in shares of Harrow Health by 4.0% in the 3rd quarter. Marshall Wace LLP now owns 26,999 shares of the company’s stock worth $326,000 after purchasing an additional 1,030 shares during the last quarter. UBS Group AG raised its position in shares of Harrow Health by 11.2% in the 4th quarter. UBS Group AG now owns 12,718 shares of the company’s stock valued at $188,000 after acquiring an additional 1,279 shares during the period. Stansberry Asset Management LLC increased its stake in Harrow Health by 1.0% during the 2nd quarter. Stansberry Asset Management LLC now owns 127,130 shares of the company’s stock worth $2,421,000 after purchasing an additional 1,306 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Harrow Health by 10.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,639 shares of the company’s stock worth $176,000 after purchasing an additional 1,523 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Harrow Health by 2.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 81,829 shares of the company’s stock worth $916,000 after purchasing an additional 1,697 shares in the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on HROW shares. B. Riley dropped their target price on shares of Harrow Health from $30.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday, March 22nd. TheStreet downgraded shares of Harrow Health from a “c-” rating to a “d+” rating in a research report on Tuesday, December 12th.

About Harrow Health

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.